KIT mutation in core-binding-factor (CBF) AML (t(8;21) / inv(16)) is enriched (~25-30%) a...
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BMA-KIT-MUTATION-AML |
|---|---|
| Type | Actionability |
| Status | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Diseases | DIS-AML |
| Sources | SRC-CIVIC SRC-ELN-AML-2022 SRC-NCCN-AML-2025 |
Actionability Facts
| Biomarker | BIO-KIT |
|---|---|
| Variant | activating mutation (exon 17 D816V / N822K most common; ~25-30% of core-binding-factor AML) |
| Disease | DIS-AML |
| ESCAT tier | IIA |
| Recommended combinations | standard 7+3 + HiDAC consolidation (CBF-AML backbone), dasatinib + 7+3 + HiDAC (CALGB-10801 trial / off-label intensification for CBF-AML KIT-mut), avapritinib (D816V-AML, basket trial) |
| Contraindicated monotherapy | imatinib (D816V-resistant; not active in CBF-AML in clinical trials) |
| Evidence summary | KIT mutation in core-binding-factor (CBF) AML (t(8;21) / inv(16)) is enriched (~25-30%) and confers worse OS vs CBF-AML wild-type. Dasatinib + 7+3 + HiDAC consolidation (CALGB-10801, Marcucci Blood 2020 — CBF-AML setting) is being studied; not standard. Avapritinib has activity in D816V-mutant AML basket cohorts but no AML approval. ELN 2022 considers KIT mutation in CBF-AML as intermediate/adverse-risk modifier within the favorable CBF subset. |
Notes
ESCAT IIA. OncoKB Level 3A. KIT testing should be performed on every CBF-AML at diagnosis; result modifies prognosis and trial eligibility but does not yet change standard-of-care chemo backbone outside trials. Trial-source gap: SRC-CALGB-10801 not yet ingested.
Used By
No reverse references found in the YAML corpus.